Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) are a new type of hypoglycemic drug that inhibit glucose reabsorption in proximal renal tubules. Except for blood glucose reduction, SGLT2 inhibitors play an important role in kidney protection. Autosomal dominant polycystic kidney disease (ADPKD) is the most common single-gene hereditary kidney disease that develops rapidly and leads to end-stage renal disease, which can significantly increase the socio-economic burden and mortality. At present, there is no effective treatment for ADPKD. This review aims to introduce the research advancement of SGLT2 inhibitors in kidney disease and the potential role in ADPKD.